Prof. Elihu (Eli) H. Estey, MD, a pioneering AML researcher, physician and scholar collapsed and died unexpectedly on Oct. 8 at his home in Seattle. He was 75.
Our good friend and colleague Ed Gehan passed away on Sept. 28 at the age of 92. Ed and his contributions to cancer research and to cancer patients are legend.
A podcast on developments in genitourinary cancer is recording oral histories with pioneers of GU oncology. Sharpless discusses the history and future of NCI at the Paul Calabresi Memorial Lecture, Nov. 2.
Proton therapy is an ultra-precise form of radiation that spares patients excess radiation to the heathy tissues and organs surrounding their tumor.
Eric P. Winer will begin his job as director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale on Feb. 1, but he has started his “listening tour” early.
The pandemic has accelerated the development of mRNA vaccines, which could have significant implications for cancer research, said Danny Milner, chief medical officer of the American Society for Clinical Pathology, and adjunct associate professor of immunology and infectious diseases in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health.
In mid-October, First Lady Dr. Jill Biden asked to visit the Hollings Cancer Center at the Medical University of South Carolina to help raise awareness of the need for breast cancer screening, education, and treatment—particularly among underserved minority women.
Stanley Reimann was just one man, but in September 1930 he faced the daunting task of sustaining a fledgling research institute, which had started in 1921 in a makeshift lab above a hospital morgue, dedicated to unraveling the causes of cancer.
Researchers have made tremendous progress in cancer prevention and treatment over the past few decades. As a result, the death rates for many common cancers are declining in the U.S.1 Unfortunately, not everyone is benefitting from these breakthroughs.
The Cancer Prevention and Research Institute of Texas will focus on finding solutions for health disparities among patients with cancer, Michelle Le Beau, the institute’s new chief scientific officer, said to The Cancer Letter.
